drugset / Trial / NCT07093333
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Phase 2
Recruiting
30 enrolled
Arialys Australia Pty Ltd
Arialys Therapeutics · collabSeoul National University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR autoantibody-associated psychiatric disease
Timeline
- Start
- 2026-05-15
- Primary completion
- 2027-11-30
- Completion
- 2028-05-30